View in EDS

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.

Saved in:
Bibliographic Details
Title: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
Authors: Gregson SJ; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Pugh K; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Patel N; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Afif-Rider S; AstraZeneca, One Medimmune Way, Gaithersburg, Maryland., Vijayakrishnan B; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Santos K; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Riedl J; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Hutchinson I; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Kang GD; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Chooi KP; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Beard R; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Adams L; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Barry CS; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Ball K; AstraZeneca, Granta Park, Cambridge, United Kingdom., Masterson LA; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., McFarlane M; AstraZeneca, Granta Park, Cambridge, United Kingdom., Hartley JA; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Howard PW; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Sep 06; Vol. 21 (9), pp. 1439-1448.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35793464
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gregson+SJ%22">Gregson SJ</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pugh+K%22">Pugh K</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Patel+N%22">Patel N</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Afif-Rider+S%22">Afif-Rider S</searchLink>; AstraZeneca, One Medimmune Way, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Vijayakrishnan+B%22">Vijayakrishnan B</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Santos+K%22">Santos K</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Riedl+J%22">Riedl J</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hutchinson+I%22">Hutchinson I</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kang+GD%22">Kang GD</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Chooi+KP%22">Chooi KP</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Beard+R%22">Beard R</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Adams+L%22">Adams L</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Barry+CS%22">Barry CS</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ball+K%22">Ball K</searchLink>; AstraZeneca, Granta Park, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Masterson+LA%22">Masterson LA</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McFarlane+M%22">McFarlane M</searchLink>; AstraZeneca, Granta Park, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hartley+JA%22">Hartley JA</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Howard+PW%22">Howard PW</searchLink>; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2022 Sep 06; Vol. 21 (9), pp. 1439-1448.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35793464
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-22-0145
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1439
    Titles:
      – TitleFull: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gregson SJ
      – PersonEntity:
          Name:
            NameFull: Pugh K
      – PersonEntity:
          Name:
            NameFull: Patel N
      – PersonEntity:
          Name:
            NameFull: Afif-Rider S
      – PersonEntity:
          Name:
            NameFull: Vijayakrishnan B
      – PersonEntity:
          Name:
            NameFull: Santos K
      – PersonEntity:
          Name:
            NameFull: Riedl J
      – PersonEntity:
          Name:
            NameFull: Hutchinson I
      – PersonEntity:
          Name:
            NameFull: Kang GD
      – PersonEntity:
          Name:
            NameFull: Chooi KP
      – PersonEntity:
          Name:
            NameFull: Beard R
      – PersonEntity:
          Name:
            NameFull: Adams L
      – PersonEntity:
          Name:
            NameFull: Barry CS
      – PersonEntity:
          Name:
            NameFull: Ball K
      – PersonEntity:
          Name:
            NameFull: Masterson LA
      – PersonEntity:
          Name:
            NameFull: McFarlane M
      – PersonEntity:
          Name:
            NameFull: Hartley JA
      – PersonEntity:
          Name:
            NameFull: Howard PW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 09
              Text: 2022 Sep 06
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1